by Jean Bedard, CEO, Circulo Pharma
Pharmaceutical organizations rarely walk into an audit unprepared. The systems are in place. The CRM captures activity. The 3PL executes fulfillment. Inventory systems track stock. Reporting exists.
And yet, audits still fail.
Not because the technology is missing, but because the technology does not operate as a controlled process.
Auditors are not evaluating whether a system exists. They are evaluating whether the organization can prove that every request, approval, shipment, receipt, return, recall, and exception followed a compliant, repeatable workflow. The moment that the chain breaks, audit risk appears.
In Canadian pharma, where expectations around traceability, accountability, and documented control are explicit, that break most often occurs in the space between systems.
The CRM-to-3PL Gap Is Where Audit Risk Lives
On paper, the process looks complete.
A sales representative submits a request through the CRM. A 3PL fulfills and ships the order. Inventory is adjusted. Reporting is generated.
But an audit does not evaluate these steps in isolation. It evaluates the continuity between them.
- Was the request valid at the moment it was made?
- Was it approved according to policy?
- Did the fulfillment align exactly with what was approved?
- Was the product eligible, in date, and authorized for that recipient?
- Can the organization prove all of that without relying on manual reconstruction?
In many organizations, the CRM holds intent, and the 3PL holds execution. The connection between the two is assumed rather than enforced. That assumption is where audit findings are born.
Without a controlled layer connecting request to fulfillment, teams are left stitching together records across systems, emails, and spreadsheets. The process may have been followed, but it cannot be proven as a single, governed workflow.
Why Fragmented Workflows Multiply Risk Across Materials
The complexity increases when different types of materials are handled differently.
From what we’ve observed with our clients is that while drug samples are usually tightly controlled and follow structured processes, defined approvals, and documented distribution. Marketing materials often don’t. They tend to move through separate vendors, ad hoc requests, shared drives, and informal communication channels.
From an operational perspective, that separation feels practical. From an audit perspective, it introduces inconsistency.
Auditors do not distinguish risk based on internal categorization. They evaluate whether the organization maintains control over what is distributed, to whom, and under what conditions. When samples, starter kits, brochures, patient materials, and clinical resources all follow different workflows, the organization cannot demonstrate a single, compliant standard of control.
Compliance Must Be Enforced Before Fulfillment
One of the most common process failures is the reliance on downstream checks.
Eligibility is reviewed after the request. Approvals are verified after submission. Expiration is checked during fulfillment. Exceptions are corrected once they are discovered.
This model assumes that compliance can be layered on top of activity. In practice, it creates gaps.
By the time a request reaches fulfillment, it should already be compliant. Authorization, eligibility, approval, and policy enforcement should be embedded at the point of action, not verified after the fact.
When compliance depends on manual review or post-process validation, it becomes inconsistent. When it is enforced within the workflow itself, it becomes repeatable and defensible. This distinction is critical in audits. Auditors are not only asking whether errors occurred. They are asking whether the process prevents noncompliant activity from occurring in the first place.
Visibility Is Not a Reporting Problem. It Is a Process Problem.
Leadership teams often believe they have visibility because they have reports. A lot of them.
Inventory reports. Shipment logs. CRM activity dashboards. 3PL summaries.
But audits do not ask for reports in isolation. They ask for continuity.
- What was available at the time of the request?
- What was requested, and by whom?
- What was approved, and under what rules?
- What shipped, and when?
- Where did it go?
- Was it valid and compliant at each step?
Answering these questions requires more than aggregated reporting. It requires a connected system where each event is part of a single, traceable chain. BUT Auditors don’t usually tell pharma companies to “buy better tech.” They tell them to prove control over the process end-to-end.
You may then want to ask yourself, “Can I reconstruct the full transaction lifecycle (not snapshots) and create an end-to-end story?” for example:
When visibility depends on pulling data from multiple systems and reconciling it manually, it is not true visibility. It is reconstruction. And reconstruction is where inconsistencies appear.
Marketing Materials Are a Hidden Source of Audit Exposure
Many organizations still treat marketing materials as operationally separate from regulated assets. The assumption is that brochures, starter kits, and patient materials carry less risk than drug samples. As a result, they are managed with less rigor.
In audits, that assumption doesn’t hold.
Health Canada guidance (GUI-0001 and GUI-0069) requires that all distributed products and samples be fully traceable, with complete and accurate records that allow reconstruction of each transaction. In parallel, the Food and Drugs Act and PAAB standards require that only approved and compliant materials be distributed and that evidence of approval and version control be maintained.
In audits, this means every distributed item must be tied to a verified approval, a specific version, and a compliant transaction record. When materials are managed outside controlled workflows, organizations cannot reliably demonstrate version control, approval status, or distribution history—creating clear compliance risk.
Every distributed item represents a controlled interaction with an HCP or patient. The organization must be able to demonstrate that the correct version was used, that it was approved, that it was distributed appropriately, and that it aligns with policy.
When marketing materials are managed outside of controlled workflows, version control breaks down. The distribution history becomes unclear. Approvals are difficult to verify. The issue is not the material itself. It is the lack of process discipline applied to it.
Organizations that pass audits treat all distributed materials as part of the same controlled system, regardless of category.
The Answer Is Not More Systems. It Is a Controlled Operational Layer.
A common response to audit risk is to add more technology. Another system for approvals. Another tool for tracking. Another reporting layer. This approach increases complexity without solving the underlying problem. And as mentioned above, no auditor is going to recommend adding more technology. That’s not their role.
Most pharmaceutical organizations already have the necessary systems in place. CRM platforms manage engagement. 3PLs manage fulfillment. ERP and WMS platforms manage inventory. DAM and CMS platforms manage content.
The issue is not the absence of systems. It is the absence of a layer that governs how those systems interact.
What is needed is a single operational layer that connects CRM activity, inventory, fulfillment workflows, and distribution into one controlled process. A layer that enforces rules at the point of action, manages handoffs between systems, and maintains a continuous, auditable record from request through delivery and beyond.
This is the role Circulo is designed to play.
Circulo sits behind the CRM as a compliance-first fulfillment engine, unifying CRM activity, fulfillment workflows, and inventory into a single audit-ready system. It does not replace existing platforms. It governs how they work together.
By connecting intent to execution, Circulo removes the gap where audit risk typically emerges.
Audit Trails Are the Proof, Not the Process
Organizations often describe their processes confidently.
They know the steps. They understand the policies. They can explain how work is supposed to happen. Auditors are not evaluating explanations. They are evaluating evidence.
- Can the organization produce a complete audit trail that shows what happened at each step?
- Can it demonstrate who initiated an action, who approved it, what rules were applied, and what the outcome was?
- Can it show that this process is consistent across all transactions, not just isolated examples?
Audit trails, role-based access logs, time-stamped records, and real-time reporting are what transform a process from theoretical to provable.
Without them, even well-designed processes become difficult to defend.
Exception Handling Is Where Audits Uncover Weakness
The standard workflow is rarely the problem.
Requests are submitted. Orders are fulfilled. Shipments are delivered.
The real test of a process is how it handles exceptions.
Returns. Destructions. Recalls. Expired inventory. Incorrect shipments. Outdated materials. Closeouts.
In many organizations, these scenarios are handled informally. Teams resolve issues through emails, manual adjustments, and one-off decisions.
From an operational standpoint, the issue is resolved. From an audit standpoint, the process is broken.
Exceptions must follow defined, documented workflows just like standard transactions. They must be tracked, approved, executed, and recorded within the same controlled system.
When exception handling is inconsistent, it creates blind spots. And those blind spots are exactly where auditors focus.
The Real Risk Is Not Technology. It Is Fragmentation
Pharma audits do not fail because companies lack systems.
They fail because the systems do not function as one controlled process.
When CRM activity, inventory, fulfillment, and distribution operate independently, the organization cannot demonstrate continuity. It cannot prove control. It cannot produce a complete, defensible record of what happened.
That is the risk.
For Canadian pharmaceutical organizations navigating complex regulatory expectations, the solution is not to replace the existing stack. It is to unify it.
Circulo was built specifically to solve this problem. By connecting CRM intent to 3PL execution, enforcing compliance at the point of action, and maintaining a continuous audit trail across every step, it transforms fragmented operations into a single audit-ready workflow.
Because in the end, audits are not passed by having the right technology.
They are passed by proving that every part of that technology operates as one controlled process.
Most pharmaceutical organizations don’t have a technology problem. They have a control problem. The systems are already in place, but without a layer that governs how they work together, audit risk lives in the gaps between them. Closing that gap means turning disconnected activity into one continuous, traceable, and controlled process from request through delivery.
Eliminate the gap between intent and execution. See how in a live demo.
